Sangui BioTech:

• Sales of USD 54,323 in first quarter

Hamburg, November 14, 2024:
In the first three months of fiscal year 2025 (to 30/06/2025) Sangui BioTech International Inc. achieved revenues from royalty income of USD 54,323. In the same period of the previous year the comparable revenue amounted to USD 20,723. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first three-month period of the year increased by 162% compared to the same period of the previous year.

Operating expenses increased USD 2,512 or 8% to USD 34,740 during the first quarter. As a result of the above factors, the three-month operating result inreased USD 31,088 from an operating loss of USD 11,505 to an operating gain of USD 19,583.

Due to the lower exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate losses from the valuation of loans denominated in EURO, a negative quarterly result of USD 20,717 was occurred. Compared to the previous year, in which a gain of USD 8,099 was achieved in the comparable period, the quarterly result worsened by USD 28,816.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---